Loading
companiesCompany
MediLink Therapeutics
MediLink developed the TMALIN ADC linker platform, licensed to Zai Lab, BioNTech, and Roche.
Also called: MediLink Therapeutics (Suzhou)MediLink Therapeutics
Overview
MediLink Therapeutics, based in Suzhou, developed the TMALIN antibody-drug conjugate linker platform, which it has licensed to Zai Lab, BioNTech and Roche. Its pipeline includes YL201, a B7-H3 ADC in phase 3 in small-cell lung cancer, ZL-6201 against LRRC15 with Zai Lab, and a c-MET ADC deal with Roche. OnCo links it to B7-H3 as a target and to Zai Lab as a partner. Whether a linker platform company can hold on to its own lead programme rather than out-license everything is the open question. The B7-H3 target page carries the competitive picture.
Headquarters
Suzhou, CN
Scorecard
All companies#253of 1244 companies, score 20
- phase 3 +6
- targets +4
- modalities +2
- registry trials +8
0 approved, 2 in phase 3, 0 earlier, 2 targets, 18 registry studies. Formula on the scorecards page.
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2024-01 | MediLink Therapeutics to Roche / Genentech YL211, c-MET ADC | Licence | $50m | about $1.0bn | source |
| 2023-10 | MediLink Therapeutics to BioNTech YL202 (BNT326), HER3 ADC on the TMALIN linker platform | Licence | $70m | more than $1.0bn | source |
Type
Website
Phase 3ADC
YL201 is an experimental antibody-drug conjugate from MediLink Therapeutics (Suzhou) in phase 3 trials for nasopharyngeal carcinoma, non-small-cell lung cancer and small-cell lung cancer, aimed at B7-H3.
Phase 3antibody-drug conjugate (ADC)
YL202 is an experimental antibody-drug conjugate (ADC) from MediLink Therapeutics (Suzhou) in phase 3 trials for non-small-cell lung cancer, HR-positive / HER2-negative breast cancer and colorectal cancer, aimed at HER3.
Similar pages
fronts
targets
drugs
companies
trials
A Clinical Study of YL205 in Patients With Advanced Solid TumorsA Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BCA Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPCA Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma(TAISHAN-301)A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer（TAISHAN-302）A Study of YL201 and Ivonescimab (AK112) in Advanced Solid TumorsA Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung CancerA Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.A Study of YL201 in Patients With Advanced Solid TumorsA Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid TumorsA Study of YL202 in Patients With Advanced Solid TumorsA Study of YL202 in Selected Patients With Advanced Solid TumorsA Study of YL242 in Subjects With Advanced Solid TumorsA Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-BasedA Study YL201 in Patients With Selected Advanced Solid TumorsPivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung CancerYL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer